Machavert
Manufacturing · Colorado, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
12635 E Montview Blvd Ste 100, Aurora, C...Phone Number
(720) 859-4053Website
www.machavert.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Machavert
Machavert Pharmaceuticals is a preclinical stage biopharmaceutical company dedicated to developing novel therapeutics for treating cancer and autoimmune diseases. The company focuses on precision medicine specifically targeting KRAS mutant cancers and utilizing bioactive phospholipids for immuno-oncology treatments. Their innovative drug delivery platform ensures selective targeting of solid tumors while minimizing impact on healthy organs. Machavert aims to improve the quality of life for patients with challenging cancers and autoimmune disorders.Explore more
Machavert Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Machavert your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Machavert has new funding data
Check if Machavert has recently received funding, and reach out quickly before it becomes old news!
Click to see if Machavert had a recent Job posting/layoffs
Earning: See what the market has to say on Machavert recently announced quarterly report
Machavert, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Machavert
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Machavert launches new products
Check out if Machavert is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Machavert
Compare insights from companies similar to Machavert, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Machavert is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Machavert is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Machavert.
Machavert financials insights
Gather financial insights about Machavert, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
Machavert Tech Stack
A closer look at the technologies used by Machavert
Most Recent Scoops
Left Company
Executive Move
Greg Miknis, Vice President of Drug Discovery, has left the organization and now serves as the Director and Senior Director of Lead Optimization Chemistry at Enveda Biosciences.
Project
A front-line source has indicated that initiatives related to vendor management & tracking have been completed within the last nine months.
Operating Systems, Logistics / Supply Chain
Project
A front-line source has indicated that initiatives related to office management system have been completed within the last nine months.
Enterprise Software, Operating Systems, Office Operations
Project
A front-line source has indicated that initiatives related to distribution & fulfillment operations are currently in progress.
Project
Machavert News & Media
Machavert Pharmaceuticals Signs Exclusive License Agreement to Control RAL GTPase Inhibitors against KRAS Cancers
AURORA, Colo., Aug. 27, 2019 /PRNewswire/ -- Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on precision medicine cancer therapies, announced today that it has obtained a full exclusive license on RAL GTPase (RAL) inhibitors from the University of Colorado....Machavert Pharmaceuticals Will Present at the Annual Meeting of the American Association of Cancer Research (AACR)
AURORA, Colo., March 29, 2019 /PRNewswire/ -- Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on immuno-oncology and precision medicine cancer therapies, announced today that it will report on the progress of its MP1115 drug candidate at the American...CEOCFO magazine interview with Machavert Pharmaceuticals CEO, Dr. Jakub Staszak-Jirkovsky
AURORA, Colo., Feb. 13, 2019 /PRNewswire/ -- Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on immuno-oncology and precision medicine cancer therapies, was featured in an interview by CEOCFO magazine. The article with the title: "Developing the first Drug...Machavert Pharmaceuticals to Present at Biotech Showcase™, 2019 in San Francisco
AURORA, Colo., Jan. 4, 2019 /PRNewswire/ -- Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on immuno-oncology and precision medicine cancer therapies, announced today that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Machavert
Sign Up For FreeTo access detailed company insights
Machavert Pharmaceuticals is a preclinical stage biopharmaceutical company dedicated to developing novel therapeutics for treating cancer and autoimmune diseases. The company focuses on precision medicine specifically targeting KRAS mutant cancers and utilizing bioactive phospholipids for immuno-oncology treatments. Their innovative drug delivery p... Read More
